Medicine and Dentistry
Doxorubicin
100%
Cardiomyopathy
100%
Carvedilol
100%
Heart Left Ventricle Ejection Fraction
71%
Therapeutic Procedure
57%
Cells
28%
DNA Damage
28%
Protein Expression
28%
Myocardium
28%
In Vitro
14%
Biological Marker
14%
Collagen
14%
Adult
14%
Male
14%
Combination Therapy
14%
Bone Morphogenetic Protein 2
14%
Oxidative Stress
14%
Endothelial Cell
14%
Cell Marker
14%
DNA
14%
Caspase 3
14%
Cell Damage
14%
Heart Failure
14%
Mitochondrial Protein
14%
Cytochrome C
14%
Poly ADP Ribose Polymerase
14%
Brain Natriuretic Peptide
14%
Cardiac Stem Cell
14%
Biochemistry, Genetics and Molecular Biology
Doxorubicin
100%
Carvedilol
100%
Heart Left Ventricle Ejection Fraction
71%
Protein Expression
28%
DNA Damage
28%
CD90
28%
Caspase 3
14%
Oxidative Stress
14%
DNA
14%
Collagen
14%
Cell Damage
14%
In Vitro Study
14%
C57BL 6 Mouse
14%
CD31
14%
Poly ADP Ribose Polymerase
14%
Mitochondrial Protein
14%
Stem Cell Marker
14%
Cytochrome C
14%
Brain Natriuretic Peptide
14%
XRCC1
14%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
100%
Cardiomyopathy
100%
Carvedilol
100%
DNA
42%
Protein
28%
C57BL 6 Mouse
14%
Collagen
14%
Biological Marker
14%
Caspase 3
14%
Bone Morphogenetic Protein 2
14%
Cytochrome C
14%
Heart Failure
14%
Mitochondrial Protein
14%
Cell Marker
14%
Brain Natriuretic Peptide
14%
Veterinary Science and Veterinary Medicine
Doxorubicin
100%
Carvedilol
100%
Ejection Fraction
71%
Mouse
14%
Natriuretic Peptide
14%
Stem Cell Marker
14%